Divi’s Laboratories shares surged to a new 52-week high of ₹7,071.50 on July 8 after HSBC upgraded the stock to Buy and sharply raised its target price to ₹7,900 from ₹5,020.
HSBC’s bullish stance is driven by a strong medium-term outlook, with significant revenue potential from high-growth segments like tirzepatide, other peptides, and contrast media. The brokerage estimates around USD 450 million in peptide revenue and USD 260 million from contrast media by 2030.
Citing Divi’s leadership in custom synthesis and complex API manufacturing, HSBC projects a 23% CAGR in earnings per share for FY25–28. The firm sees Divi’s benefiting from the global trend of outsourcing complex molecules, boosting profitability and margins over time.
The stock opened at ₹7,002 and hit an intraday low of ₹6,972.50 before climbing to its fresh peak. Divi’s Laboratories’ previous 52-week low stood at ₹4,395.30.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
